Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction

医学 心力衰竭 射血分数保留的心力衰竭 射血分数 内科学 心脏病学 内分泌学 药理学 生物信息学 生物
作者
Arjun Pandey,Deepak L. Bhatt,Avinash Pandey,Nikolaus Marx,Francesco Cosentino,Ambarish Pandey,Subodh Verma
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:44 (37): 3640-3651 被引量:20
标识
DOI:10.1093/eurheartj/ehad389
摘要

For decades, heart failure with preserved ejection fraction (HFpEF) proved an elusive entity to treat. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to reduce the composite of heart failure hospitalization or cardiovascular death in patients with HFpEF in the landmark DELIVER and EMPEROR-Preserved trials. While improvements in blood sugar, blood pressure, and attenuation of kidney disease progression all may play some role, preclinical and translational research have identified additional mechanisms of these agents. The SGLT2 inhibitors have intriguingly been shown to induce a nutrient-deprivation and hypoxic-like transcriptional paradigm, with increased ketosis, erythropoietin, and autophagic flux in addition to altering iron homeostasis, which may contribute to improved cardiac energetics and function. These agents also reduce epicardial adipose tissue and alter adipokine signalling, which may play a role in the reductions in inflammation and oxidative stress observed with SGLT2 inhibition. Emerging evidence also indicates that these drugs impact cardiomyocyte ionic homeostasis although whether this is through indirect mechanisms or via direct, off-target effects on other ion channels has yet to be clearly characterized. Finally, SGLT2 inhibitors have been shown to reduce myofilament stiffness as well as extracellular matrix remodelling/fibrosis in the heart, improving diastolic function. The SGLT2 inhibitors have established themselves as robust, disease-modifying therapies and as recent trial results are incorporated into clinical guidelines, will likely become foundational in the therapy of HFpEF.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xjcy应助哈哈哈采纳,获得20
1秒前
小马甲应助ascdu采纳,获得10
1秒前
99c关注了科研通微信公众号
1秒前
六妜发布了新的文献求助10
2秒前
shin0324发布了新的文献求助10
2秒前
2秒前
2秒前
zyt完成签到,获得积分10
2秒前
lulujiao发布了新的文献求助10
3秒前
3秒前
Nerissa完成签到,获得积分10
4秒前
星辰大海应助WANG采纳,获得10
4秒前
5秒前
医平青云发布了新的文献求助10
5秒前
Dora发布了新的文献求助10
7秒前
完美世界应助jiabao采纳,获得10
7秒前
飘锅完成签到,获得积分10
7秒前
小何完成签到,获得积分10
8秒前
小黄不慌完成签到,获得积分10
8秒前
8秒前
wwwteng呀完成签到,获得积分10
9秒前
夷陵老祖胃无限完成签到,获得积分10
9秒前
9秒前
活力霸发布了新的文献求助10
9秒前
9秒前
9秒前
我和狂三贴贴完成签到,获得积分10
9秒前
11秒前
99c发布了新的文献求助20
12秒前
小何发布了新的文献求助10
12秒前
Roxy完成签到,获得积分20
13秒前
xiaoliu发布了新的文献求助10
13秒前
SUSE_HJX发布了新的文献求助10
13秒前
12305014077发布了新的文献求助10
14秒前
14秒前
15秒前
16秒前
17秒前
Alberta完成签到,获得积分10
17秒前
疏狂发布了新的文献求助10
19秒前
高分求助中
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 800
Ethnicities: Media, Health, and Coping 700
Development of a new synthetic process for the synthesis of (S)-methadone and (S)- and (R)-isomethadone as NMDA receptor antagonists for the treatment of depression 500
A Dissection Guide & Atlas to the Rabbit 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3089386
求助须知:如何正确求助?哪些是违规求助? 2741586
关于积分的说明 7565941
捐赠科研通 2392093
什么是DOI,文献DOI怎么找? 1268497
科研通“疑难数据库(出版商)”最低求助积分说明 614069
版权声明 598692